Recently, remarkable advances have been achieved in molecular and genetic researches of different kinds of general diseases, as well as in basic and clinical studies using gene therapy for central nervous system diseases. For brain tumors, clinical trials have been already started in more than 10 clinical pro tocols and more than 100 patients with malignant brain tumors. Nevertheless, there are still major is sues that remain to be resolved for achieving better clinical results, such as delivery system of genetic material, regulatory methods of the intracellular expression of the transgene, antitumor efficacy, and tumor selectivity. In this paper, molecular genetic studies and the current state of gene therapy for neu rological diseases, especially brain tumors, are described, and the future direction of this fascinating ap proach is discussed.
Introduction
In the last 10 years, gene therapy in clinical reality has been proposed for several kinds of inherited and acquired diseases. The first authorized human gene therapy was started in the U.S.A. on September 14, 1990 on 4-year-old girl who had been born with a defective adenosine deaminase (ADA) gene which caused severe combined immunodeficiencies. With a combined treatment consisting of gene transfer of the ADA gene and administration of polyethylene glycol-ADA, she is apparently in good health without any side effects.
Since this successful treatment, a variety of hu man gene therapy protocols have occurred worldwide.") According to the worldwide gene ther apy report by TMC development in France, more than 2500 patients are enrolled in these protocols as of June 1996. Most trials are performed in the U.S.A. and European countries, with a few in Asian coun tries including Japan. Target diseases for this ther apy are expanding from congenital metabolic disord ers to encompass acquired life-threatening diseases such as cancer and acquired immunodeficiency syn drome (AIDS). Chronic benign diseases are also ex pected to be a focus of this therapy. At present, can cer is by far the most popular protocol, involving 848 patients. AIDS (372 patients), cystic fibrosis (152 patients), leukemia/myeloma (89 patients) are sec ond, followed by arterial disease (16 patients) and ADA deficiency (12 patients).
Gene Therapy Approaches for General Disorders
Three different approaches are proposed for human gene therapy: 1) Genes of interest are delivered into patients in vivo or ex vivo in order to produce ther apeutic materials, 2) amplification of normal gene or suppression of abnormal gene by antisense ribonucleic acid or ribozyme, and 3) replacement of abnormal gene to normal gene by homologous recombination and repaired genomic deox yribonucleic acid (DNA). Most protocols approved by the Recombinant DNA Advisory Committee (RAC) involve the first approach, which contains three key components: a) the vector, b) the gene of in terest, and c) the target cells. The vectors for gene transfer are classified into viral and non-viral. Until now several kinds of vector systems have been used for central nervous system (CNS) gene transfer, that is included retroviruses, recombinant herpes sim plex virus (HSV), adenoviruses, adeno-associated viruses (AAVs), and liposome-entrapped plasmid vector (Table 1) developed a cationic liposome with N-{1-(2,3-dioley oxy)propyl}-N,N,N-trimethylammonium (DOTMA). The authors reported the DOTMA interacts spon taneously with DNA to form a DNA-lipid complex and facilitates fusion of the complex with the cell membrane, resulting in both uptake and expression of the DNA. Since this basic work, cationic liposome mediated gene transfer has been widely used in the field of molecular biology and for gene therapy studies.",") Several groups have explored more ef ficient and less toxic cationic liposome composi tions using different cationic lipids.7) We have also developed novel cationic liposomes with high trans fection efficiency and low cytotoxicity which permit their use for in vivo gene transfer. 17) Our liposomes are multilamellar vesicles prepared by a simple procedure with N-(a-trimethyl ammonioacetyl) didodecyl-D-glutamate chloride (TMAG), dilauroyl phosphatidylcholine, and dioleoyl phosphatidyletha nolamine in a molar ratio of 1:2:2.38) To transfer the gene selectively and efficiently into target cells, we coupled a monoclonal antibody (MCA) with the lipo somes and made immunoliposome s.41) For this pur pose, we developed two MCAs (G-22 and 3C10) against cell surface molecules expressed on human glioma cells. G-22 MCA operates against the stan dard or hematopoietic form of CD44, which is known to be overexpressed in the cell adhesion molecules on most glioma cells.12,33) 3C10 MCA oper ates against the truncated epidermal growth factor receptor (EGFR), encoded by the type III in-frame de letion mutant.24) It has been identified in about 10 20% of glioblastoma patients. In our experiments, the proportion of glioma cells that expressed the transfered DNA sequences and the absolute levels of expression obtained were markedly higher when the DNA/immunoliposomes were used, compared to the levels achieved with the DNA/liposomes.41)
Concept
Approaches for Gene Therapy of CNS Disorders
The basic study of gene therapy for the CNS disord ers have been investigated in several directions. Un til now, at least three categories of CNS diseases could be classified according to the possible mode of gene therapy: 1) Gene replacement therapy for in herited or acquired neurodegenerative disorders us ing transfected cells ex vivo. 2) Gene therapy of stroke or neurovascular diseases. 3) Gene therapy of brain tumors, not only solid mass but also CNS dis seminated meningitis. As for protection of neurons from programmed cell death caused by ischemic injury, gene targeting or genetic transfer of components of interleukin-1 receptor antagonist protein,') Bcl-2,12) nerve growth factor 2') neuronal apoptosis inhibitory protein,") and glucose transporter gene") have been investigat ed so far.
As for the control of expression of different inflam matory mediators in brain, several kinds of cytokines that are produced in response to an ischemic insult and are involved in the development of brain injury may offer novel therapeutic strate gies.
Gene therapies of brain tumors will be described in the next section.
Characteristics of CNS Tumors
In the last decade, the prognosis of brain tumor patients has dramatically improved due to recent ad vances in microneurosurgical techniques and the de velopment of functional neuroimaging, computer-as sisted neuronavigation system, endoscopic surgery, intravascular surgery, radiosurgery, and so on. Ac cording to a report by the Committee of Brain Tumor Registry of Japan, the 5-year survival rate of patients with benign brain tumors (meningioma, neurinoma, and pituitary adenoma) is more than 95%. In contrast, patients with glioma (which con stitute 33% of primary brain tumor cases) still have a poor prognosis, especially in the case of malignant types (anaplastic astrocytoma and glioblastoma) (Ta ble 2). This poor prognosis is related to the fact that malignant glioma cells aggressively infiltrate into normal brain tissues, making total removal of the tumor impossible. The median survival time of glio blastoma patients is less than 2 years, despite mul timodality treatment with extensive surgical resec tion and adjuvant therapies using radiotherapy and immunochemotherapy.4o) ,23) and tenascin46) were reported to be strongly correlated with the invasion of tumor cells. For these reasons, total resection of gliomas by surgery is impossible, although recent advances in microsur gical technique are remarkable. Recently, postopera tive radiation has been applied to all patients with malignant glioma. The tumors do show a response to the radiation in many cases, but relatively high doses are necessary to achieve control of the tumor growth. The normal brain around the tumor can generally tolerate no more than 60 Gy, which is be low the curative level for glioma.
Other approaches to malignant glioma treatment have included chemotherapy using nitrosourea derivatives either as an adjuvant to radiation 31) or at the time of relapse, and immunotherapy with interfe ron-/l (IFN-a),40) intratumoral lymphokine-activated killer cell instillation '16) intra-arterial tumor necrosis factor-a (TNF-a) infusion,") and intratumoral injec tion of radiolabeled MCAs.44) These adjuvant thera pies help to prolong survival at least for anaplastic astrocytoma. However, none of these methods are curative, and the median survival time for malignant glioma patients is less than 2 years at present. Never theless, this malignant glioma has important fea tures which make it an excellent candidate for gene therapy. The brain is a closed cavity separated from the general circulation system by the blood-brain bar rier, and it has been noted to be an immunologically privileged site with no lymphatic system. Normal glia and neuron are relatively quiescent compared to tumor cells. Futhermore, the glioma arising from a glia is a localized tumor in the CNS with no extra CNS metastasis.
Fundamental
Studies of Gene Therapy for CNS Tumor Two gene therapy approaches were studied for the treatment of malignant CNS tumors, which have been already applied for clinical trial: 1) suicide gene therapy using the HSV thymidine kinase (HSV tk) gene and ganciclovir (GCV) and 2) immune gene therapy using cytokine genes. Adenovirus vectors have the advantage that high titers can be obtained and cell-free virus can be ad ministered in vivo. Adenovirus does not integrate into the genome, thereby reducing the risk of inser tional mutagenesis. The vector is also able to infect non-dividing quiescent tumor cells and conse quently kill these cells at the time of their entry into the cell cycle when GCV is provided. Several investi gators have demonstrated that treatment of ex perimental glioma and leptomeningeal metastases with adenovirus vectors harboring the HSV-tk gene was not associated with toxicity. Recombinant adenoviruses thus have potential to be used as vec tors in suicide gene therapy of CNS tumors in hu mans. But when clinical use is considered, more fun damental research concerning interaction of tumor cell rate division and killing efficiency should be in vestigated. A team from Howard Hughes Medical In stitute (Chevy Chase, Md., U.S.A.) and the Baylor College of Medicine (Houston, Tex., U.S.A.) report ed the efficacy of adenovirus-mediated gene therapy to treat brain tumor.') Tumors were generated in syn geneic rats by stereotactic implantation of 9L gliosar coma cells into the caudate nucleus. Eight days later, the tumors were injected and transduced in situ with a replication-defective adenovirus carrying the HSV-tk gene, and the rats were treated with GCV. No tumors were detected in animals treated with adenovirus thymidine kinase and GCV.
We are developing a gene therapy using the AAV vector and have demonstrated the efficacy of AAV vector-based gene therapy for malignant glioma in an experimental animal model. We obtained AAV vectors containing the gene for either HSV-tk (AAV tk) or 8-galactosidase (AAV-LacZ) from Avigen Inc.
(Alameda, Calif., U.S.A.). In several experiments, we confirmed that gene expression was seen in more than 30% of glioma cells by intratumor injection of the AAV-LacZ vector. Following a single injection of an AAV-tk or AAV-tk-Internal Ribosome Entry Seg ment (IRES)-interleukin-2 vector into human glioma implanted into the brains of nude mice, a significant reduction in tumor size was observed in all animals who also received GCV.21) Furthermore, after multi ple AAV-tk injections intratumorally followed by in traperitoneal GCV administration, complete regres sion of the intracerebral implanted human glioma could be obtained, and the survival period of host mice was also prolonged remarkably.") With respect to immune gene therapy, as in our other experimental studies, we also investigated how to make transfected human glioma cells with a plasmid vector containing the human IFN-/3 (HuIFN-/3) gene (pSV2IFN-/3) by means of our novel TMAG cationic liposome, and found that HuIFN-f produced in the cells had a much stronger inhibitory effect on the growth of the tumor cells than ex ogenously added HuIFN-f.17) Our results suggest that the mechanism causing the growth-inhibitory ef fect of transfection-induced HuIFN-/3 is different from the exogenous one. The former process is thought to be cytocidal to the transfected glioma cells, which can be ascribed to HuIFN-/3 production in the cells transfected with its gene by the process of apoptosis. 17'43) In vivo experiments using transplanted human glioma growing in the brain of nude mice clearly showed that HuIFN-8 was expressed in the solid tumor and that growth of the brain tumor was in hibited by intratumoral injection of liposomes with entrapped pSV2IFN-/3, while a high dose of ex ogenous HuIFN-/3 or empty liposomes did not sig nificantly inhibit the growth of human glioma.37) Interestingly, the production of HuIFN-/3 in the cells and its release from the transfected cells were increased by treating cells with a small dose of TNF a before transfection.
Correspondingly, the an titumor effect of the transfection-induced HuIFN-f was significantly elevated by combination with TNF-a.42) The intraperitoneal injection of a small amount of TNF-a inhibited tumor growth only slight ly. On the other hand, prior treatment with TNF-a followed by intratumoral injection of liposomes with entrapped pSV2IFN-/3 had a remarkable effect. The subcutaneous tumors regressed completely in all nude mice tested; they were tumor free and sur viving for long follow-up period. In our experimental studies of brain tumors, we found that human TNF-a (HuTNF-a) was produced in the glioma cells transfected with liposomes with entrapped pcDVTNF-a and that the growth-inhibito ry effect of transfection induced HuTNF-a was much stronger than that of exogenously added HuTNF-a.6) In our study to analyze this mechanism, we found that it was due to transmembrane-formed TNF-a.
Using this liposomal transfection strategies to clarify the effect of glial fibrillary acidic protein (GFAP) expression in brain tumor cells, we also transferred the GFAP gene into the human medullo blastoma cell line, DAOY-1, which lacks the expres sion of GFAP. As a result, after GFAP gene transfec tion, growth inhibition and increase of sensitivity to anticancer drug (cisplatinum) were observed with GFAP expression in the cells. These results indicate that gene therapy also may become one of the ad juvant treatment methods combined with conven tional chemotherapy. 29) Since the first human gene therapy started success fully, more than 100 protocols have been approved by the RAC, and clinical application has been car ried out in more than 2500 patients worldwide. As for CNS tumors, 11 protocols have been approved so far and more than 100 patients treated by gene ther apeutic methods (Table 3) .8) Gene therapy has been conducted mostly in university hospitals and at other U.S.A. and European academic centers, sup ported by the National Institute of Health (NIH) and private companies. However, an ad hoc NIH com mittee assessing the current state of gene therapy in 1995 found that its clinical efficacy had not been definitively demonstrated in any gene therapy pro tocol, because significant problems remain with all basic aspects of gene therapy. In order to confront the major outstanding obstacles to successful gene therapy, the committee recommended a greater fo cus on basic aspects of gene transfer and gene ex pression, and an emphasis on research dealing with the pathogenesis of target diseases. Furthermore, the negatives associated with the concepts of gene ther apy, in addition to the delivery that probably remains a major obstacle, are transient gene expres sion, toxicity of viral proteins, and the problem of im mune response to the transfected protein.
Advances in gene therapy in progress will really depend on the development of gene delivery systems into the target cells. As for the methods resolving this problem, Zlokovic and Apuzzo48) emphasize the development of techniques which circumvent the im permeable blood-brain barrier and ways to breach the more versatile blood-brain-tumor barrier to deliver the genetic material to the target CNS cells. These include the following: 1) Local stereotactic CNS injection/infusion of viral vectors, administra tion of VPCs, or cell replacement; 2) local adminis tration of genetic material into the cerebrospinal fluid ventriculocisternal system; 3) osmotic opening of the blood-brain barrier; 4) local intra-arterial in fusion; and 5) administration of blood-brain-tumor barrier permeabilizers, such as bradykinin B2 an tagonist.
Furthermore, in the future, as Rutka mentioned in a comment to the article of Zlokovic and Apuzzo,47) all gene therapy strategies still have to overcome at least two major obstacles. One is the significant im mune response, which is invoked in the host when viruses, bacteria, or heterologous cell types are used for gene transfer. The other is the difficulty with brain specific targeting of vectors to the CNS. Though there is still little evidence that current gene therapy in clinical use can achieve tumor regression or cure, after resolving such issues which described already, we expected that gene therapy will become one of the standard treatment choices for several kinds of diseases including CNS tumors. 
